Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Online

US Regulatory and Compliance Considerations

Enhance your knowledge of regulations and guidelines for sharing drug product information in the United States.

Overview

This module provides an overview of the regulations and guidance that govern the dissemination of information about drug products. It's focus is on governance in the United States. Other countries and regions have their own governing agencies with regulations that may or may not reflect those discussed here.

Featured topics

  • FDA Jurisdiction Over Prescription Drug Advertising and Promotional Labeling
  • FDA Regulatory Standards for Advertising and Promotional Labeling
  • Requirements for Advertising and Promotional Labeling
  • Special Types of Advertising and Promotional Events
  • Promotion versus Scientific Exchange and Solicited versus Unsolicited Information
  • On-Label and Off-Label Considerations
  • Direct-To-Consumer Promotion
  • Compliance and other law enforcement agencies

Who should attend?

  • This course is designed for professionals involved in:

    • Medical affairs
    • Medical communications
    • Medical information
    • Medical writing
    • Field-based medical affairs support (i.e., Medical Science Liaison)
    • Medical call center environment
    • Regulatory affairs
    • Clinical research
    • Professional education, training, and development
    • Document management/eSubmissions

    Learning objectives

    Upon completion of this module, learners should be able to:

    • Identify the authority and jurisdiction under which the FDA regulates the dissemination of information, including advertising and promotional labeling, about prescription drugs
    • Recognize the regulatory requirements for prescription drug advertisements and promotional labeling
    • Define the issues concerning the dissemination of information about a prescription drug product prior to its approval
    • Determine issues around special types of advertising and promotional events and how they relate to healthcare professionals
    • Identify on-label and off-label issues concerning approved prescription drugs and the issues concerning the dissemination of off-label information
    • Recognize what information is classified as "scientific exchange" versus "promotional"
    • Define the issues concerning direct-to-consumer advertising of prescription drugs
    • Determine the interests of FDA and other federal and state law enforcement agencies in monitoring the dissemination of information about prescription drugs

    Have an account?

    Be informed and stay engaged.

    Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.